Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2024). The first MASH drug therapy on the horizon: Current perspectives of resmetirom. Liver International, 44(7), 1526–1536. Portico. https://doi.org/10.1111/liv.15930

Yang, W., Ebrahimi, F., Romeo, S., Holmer, M., Vessby, J., Ekstedt, M., Ludvigsson, J. F., Shang, Y., & Hagström, H. (2024). Risk of major adverse liver outcomes among first‐degree relatives of individuals with MASLD. Liver International, 44(5), 1253–1264. Portico. https://doi.org/10.1111/liv.15874

Ebrahimi, F., Simon, T. G., Hagström, H., Sun, J., Bergman, D., Forss, A., Roelstraete, B., Engstrand, L., & Ludvigsson, J. F. (2023). Antibiotic use and development of nonalcoholic fatty liver disease: A population‐based case–control study. Liver International, 43(10), 2186–2197. Portico. https://doi.org/10.1111/liv.15663

Shang, Y., Widman, L., Ebrahimi, F., Ludvigsson, J. F., Hagström, H., & Wester, A. (2023). Risk of infections in non‐alcoholic fatty liver disease: A nationwide population‐based cohort study. Liver International, 43(10), 2142–2152. Portico. https://doi.org/10.1111/liv.15680

Jiménez, C., Ventura‐Cots, M., Sala, M., Calafat, M., Garcia‐Retortillo, M., Cirera, I., Cañete, N., Soriano, G., Poca, M., Simón‐Talero, M., Altamirano, J., Lucey, M., Garcia‐Tsao, G., Brown, R. S., Schwabe, R. F., Verna, E. C., Schnabl, B., Bosques‐Padilla, F., Mathurin, P., … Vargas, V. (2022). Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH). Liver International, 42(5), 1109–1120. Portico. https://doi.org/10.1111/liv.15207